AzTrials
AzTrials

Esophageal Squamous Cell Carcinoma (ESCC)Phase 2NCT06078657

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

A Phase 2 study testing IBI110+Sintilimab in people with Esophageal Squamous Cell Carcinoma (ESCC) and PD-1 Inhibitors, run by The First Affiliated Hospital of Zhengzhou University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a single-center, prospective, single-arm Phase II clinical study to evaluate the efficacy and safety of IBI110 in combination with Sintilimab in subjects with advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have failed first-line treatment with PD-1 inhibitors combined with chemotherapy. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
IBI110+Sintilimab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
1 siteChina
Study dates
Oct 2023to Oct 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Sign written informed consent prior to the implementation of any procedures related to the trial, and be able to comply with protocol visits and related procedures;
  • Age ≥18 years old and ≤75 years old;
  • Unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma confirmed by histopathological examination (excluding adenosquamous cell carcinoma mixed type and other pathological types);
  • Disease progression must have previously received first-line anti-PD-1 antibody combined with chemotherapy, and disease progression must occur after at least 2 imaging evaluations after anti-PD-1 therapy (the second imaging evaluation is not less than 84 days after the first anti-PD-1 therapy); And the best efficacy evaluation of CR or PR population; It takes ≥6 months for the disease to stabilize in SD population.
  • First-line chemotherapy includes fluorouracil combined with cisplatin or paclitaxel combined with cisplatin;
  • Did not receive any systematic therapy, such as chemotherapy, targeted therapy, immunotherapy or other therapy, for 21 days before enrollment;
Show all 23Show fewer
  • Occurrence of immune-related adverse events during prior treatment with anti-PD-1 antibodies, except for the following: a.Grade 3 or higher immune-related adverse events (ir-AE) occurred, except for asymptomatic non-bullous or non-exfoliating rashes;b.did not recover from grade 2 immune-related adverse events (ir-AE);c.any adverse events leading to permanent discontinuation of PD-1;
  • Note: Any level of toxicity that requires replacement therapy and is stable (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is permissible.
  • There was at least one radiographically measurable lesion according to the solid tumor efficacy evaluation criteria (RECIST v1.1 edition).
  • ECOG score 0-1;
  • Expected survival time >3 months;
  • For adequate organ function, the subject must meet the following laboratory criteria:
  • The absolute value of neutrophil (ANC) ≥1.5x109/L in the past 14 days without the use of granulocyte colony-stimulating factor;
  • Platelets ≥100×109/L without blood transfusion in the past 14 days;
  • Hemoglobin >9g/dL in the last 14 days without blood transfusion or use of erythropoietin;
  • Total bilirubin ≤1.5× upper limit of normal (ULN);
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤2.5×ULN (ALT or AST ≤5×ULN for subjects with liver metastasis);
  • Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min;
  • Good coagulation function, defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN;
  • Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled;
  • The myocardial enzyme profile was within the normal range (if the researcher comprehensively judged that the simple laboratory abnormality was not clinically significant, it was also allowed to be included);
  • For female subjects of reproductive age, a urine or serum pregnancy test should be performed negative within 3 days prior to receiving the first study drug administration (day 1 of cycle 1). If the urine pregnancy test results cannot be confirmed as negative, a blood pregnancy test is requested. Women of non-reproductive age were defined as at least one year after menopause or having undergone surgical sterilization or hysterectomy;
  • If there is a risk of conception, all subjects (male or female) are required to use a contraceptive with an annual failure rate of less than 1% for the entire duration of treatment up to 120 days after the last study drug administration (or 180 days after the last study drug administration).

Who cannot join

  • Esophageal squamous cell carcinoma known to be prone to complete obstruction under endoscopy requires interventional therapy to relieve the obstruction;
  • After stent implantation in esophagus or trachea; Patients who are at high risk of bleeding or perforation due to significant tumor invasion of adjacent organs (aorta or trachea), or who have developed fistulas;
  • Malignant diseases other than esophageal cancer diagnosed within 3 years prior to initial administration (excluding radical basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and/or carcinoma in situ after radical resection);
  • An active autoimmune disease requiring systemic treatment (e.g. with disease-modifying drugs, glucocorticoids, or immunosuppressants) has occurred within 2 years prior to initial administration. Replacement therapies (such as thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy;
  • Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
  • Allergy to Sintilimab, IBI110 active ingredients or excipients of this study is known;
Show all 39Show fewer
  • Prior treatment with anti-LAG-3 antibodies;
  • Has not fully recovered from toxicity and/or complications caused by any intervention before starting treatment (i.e., ≤ grade 1 or baseline, excluding weakness or hair loss);
  • Received the following treatment:
  • Received systemic anti-tumor therapy within 3 weeks before treatment, such as chemotherapy, targeted therapy, immunotherapy (including Chinese herbal therapy with anti-tumor indications), etc.;
  • Received any investigational drug therapy within 4 weeks prior to treatment;
  • Receiving excessive doses of immunosuppressive drugs (systemic corticosteroids exceeding 10mg/ day of prednisone or its equivalent) within 4 weeks prior to treatment;
  • Received live attenuated vaccine within 4 weeks prior to treatment (or plan to receive live attenuated vaccine during the study period);
  • Major surgery, or unhealed surgical wounds, ulcers, or fractures within 4 weeks prior to treatment.
  • An active autoimmune disease requiring systemic treatment (e.g. with disease-modifying drugs, glucocorticoids, or immunosuppressants) has occurred within 2 years prior to first administration. Replacement therapies (such as thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic therapy;
  • Known allogeneic organ transplantation (other than corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
  • People who are known to be allergic to the active ingredient or excipient of Sintilimab in this study;
  • Has not fully recovered from toxicity and/or complications caused by any intervention before starting treatment (i.e., ≤ grade 1 or baseline, excluding weakness or hair loss);
  • Known history of human immunodeficiency virus (HIV) infection (i.e., HIV1/2 antibody positive);
  • Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number detected greater than the upper limit of normal value in the laboratory of the study center);
  • Note: Hepatitis B subjects who meet the following criteria can also be enrolled:
  • HBV viral load <1000 copies /ml (200IU/ml) prior to initial administration, subjects should receive anti-HBV therapy throughout the study chemotherapy drug treatment to avoid viral reactivation
  • For subjects with anti-HBC (+), HBsAg (-), anti-HBS (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring of viral reactivation is required
  • Active HCV-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection);
  • Pregnant or lactating women;
  • The presence of any serious or uncontrolled systemic disease, such as:
  • The resting electrocardiogram has major abnormal rhythm, conduction or morphology, such as complete left bundle branch block, heart block above Ⅱ degree, ventricular arrhythmia or atrial fibrillation;
  • Unstable angina pectoris, congestive heart failure, New York Heart Association (NYHA) grade ≥2 chronic heart failure;
  • Any arterial thrombosis, embolism or ischemia occurred within 6 months before treatment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack;
  • Poor blood pressure control (systolic > 140mmHg, diastolic > 90mmHg);
  • There is a history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year prior to first administration, or there is currently clinically active interstitial lung disease;
  • Active pulmonary tuberculosis;
  • There is an active or uncontrolled infection that requires systemic treatment;
  • Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction;
  • Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  • Poor diabetes control (fasting blood glucose (FBG) > 10mmol/L);
  • Urine routine indicated urine protein ≥++, and confirmed 24-hour urine protein quantity > 1.0g;
  • Patients with mental disorders who cannot cooperate with treatment;
  • Medical history or evidence of disease that may interfere with the test results, prevent participants from participating fully in the study, abnormal treatment or laboratory test values, or other conditions that the investigator considers unsuitable for enrollment. The Investigator considers that there are other potential risks that are not suitable for participation in the study.

Trial locations and contacts

1 site in 1 country.

China1 site

  • Feng Wang

    Zhengzhou, Henan, 450052

Other trials in China

About this study

Official title: Prospective, Single-arm Phase II Exploratory Study of the Efficacy and Safety of IBI110 Combined With Sintilimab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma That Has Failed First-line Anti-PD-1 Antibody Therapy

This is a single-center, prospective, single-arm Phase II clinical study to evaluate the efficacy and safety of IBI110 in combination with Sintilimab in subjects with advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have failed first-line treatment with PD-1 inhibitors combined with chemotherapy.

Patients who meet the inclusion criteria will be treated with IBI110 combined with Sintilimab until disease progression, death, toxicity intolerance, withdrawal of informed consent, initiation of new anti-tumor therapy, or termination of therapy for other reasons specified in the protocol. RECIST v1.1 was used for clinical tumor imaging evaluation every 6 weeks during treatment.

Being tested
IBI110+Sintilimab
Medical subject headings
Esophageal Squamous Cell Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IBI110+SintilimabDrug

    IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.

    Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years.

Study groups in NCT06078657
Study groupRoleWhat they receive
IBI110 combined with SintilimabExperimentalNot described
Receives: Drug: IBI110+Sintilimab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 1 year overall survival rate

    The proportion of participants who were alive in the study from treatment to 1 year

    Measured: 1 year

Secondary outcomes (5)

  1. overall survival and progression free survival

    The time between the start of treatment and the first progression disease or death (whichever occurs first) from any cause

    Measured: about 2 years

  2. objective remission rate

    The proportion of total subjects in complete response (CR) and partial response (PR);

    Measured: about 2 years

  3. Disease control rate

    The proportion of subjects in complete response (CR), partial response (PR) and stable disease (SD) to total subjects;

    Measured: about 2 years

  4. Duration of remission

    The time between the first partial response or complete response and progression disease or death (whichever occurs first) from any cause

    Measured: about 2 years

  5. adverse events

    adverse events (AEs) categorized by severity in accordance with the CTC AE Version 5.0

    Measured: about 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Oct 2023
  2. Study startOct 2023 (estimated)
  3. Primary completionOct 2024 (estimated)
  4. Study completionOct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
46 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06078657
Sponsor's protocol ID
CIBI110Y006
Status last verified
Oct 2023
First submitted
21 Sep 2023
Last updated
12 Oct 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing IBI110+Sintilimab in people with Esophageal Squamous Cell Carcinoma (ESCC) and PD-1 Inhibitors, run by The First Affiliated Hospital of Zhengzhou University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

1 year overall survival rate (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06078657.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2023; AzTrials last refreshed its copy on 6 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in